Background {#Sec1}
==========

Measurement of non-allergic or non-specific airway hyperresponsiveness (AHR) is a valuable tool in the clinical assessment of patients with possible asthma, those with asthma-like symptoms and non-diagnostic, generally normal, lung function. Stimuli used to measure AHR have been classified as direct and indirect \[[@CR1]\]. Direct stimuli act directly on airway smooth muscle receptors; examples include methacholine acting on muscarinic receptors and histamine acting on H~1~ receptors. Indirect stimuli act through one or more intermediate pathways most via mediators released from metachromatic inflammatory cells (mast cells, basophils); examples include exercise, eucapnic voluntary hyperpnea (EVH), non-isotonic aerosols, propranolol, adenosine monophosphate (AMP) and dry powder mannitol \[[@CR2]\]. Direct AHR reflects airway smooth muscle function, perhaps modulated by inflammation, while indirect AHR reflects airway inflammation \[[@CR1], [@CR2]\]. The consensus is that direct AHR is highly sensitive for current asthma whereas indirect AHR is highly specific while being relatively insensitive particularly for mild and/or well controlled asthma \[[@CR2]\].

Dry powder mannitol (Aridol^®^) inhalation is an indirect challenge test \[[@CR3]\] with several advantages. The advantages include the dose--response nature of the test (in contrast particularly to exercise and EVH), the lack of requirement for expensive and bulky equipment, and the fact that there is only a single method for administration of mannitol. In addition, we suspect that the mannitol challenge is less likely to be dose limited compared to other indirect challenges such as exercise, EVH, propranolol or AMP.

Studies comparing the diagnostic properties of the direct methacholine challenge and the indirect mannitol challenge have yielded conflicting results \[[@CR3]--[@CR29]\]. Several studies show that the two challenges have unexpectedly comparable sensitivity for asthma \[[@CR7], [@CR12], [@CR13], [@CR15]\] whereas other studies support the consensus that methacholine is more sensitive for a diagnosis of asthma \[[@CR19], [@CR22], [@CR25], [@CR26], [@CR29]\]. A possible explanation is the observation from numerous studies that methacholine methods using a dosimeter with total lung capacity (TLC) inhalation (with a breath hold) demonstrate a marked loss of diagnostic sensitivity \[[@CR30]--[@CR32]\] due to deep inhalation bronchoprotection. This results in false negative challenges occurring in as many as 25% of overall methacholine tests and approaching 50% in asthmatics with mild AHR \[[@CR33]\].

We hypothesized that deep inhalation methacholine methods with resulting bronchoprotection may be the explanation for conflicting sensitivity/specificity data. We have compared the diagnostic performance of the two challenges by examining studies where the two tests were performed in the same individuals (mostly) and where the methacholine inhalation method was clearly described.

Methods {#Sec2}
=======

Saskatoon studies {#Sec3}
-----------------

We began by identifying 46 unique individuals from four studies performed in our laboratory. We included the 20 subjects from the most recent study \[[@CR29]\], 18 (of 20) additional subjects from a second study \[[@CR26]\] and 8 (of 20) subjects from two allergen challenge studies \[[@CR27], [@CR28]\]. For analysis we selected the first methacholine challenge performed in the four studies, the only mannitol study by the standard method \[[@CR3]\] from 2 studies \[[@CR26], [@CR29]\] and the pre-allergen mannitol challenge from the two allergen challenge studies \[[@CR27], [@CR28]\]. The methacholine challenges were done with the two minute tidal breathing method \[[@CR34]\] in three studies \[[@CR26]--[@CR28]\] and by the tidal breathing vibrating mesh nebulizer volumetric method (0.5 mL methacholine nebulized to completion, 1.5 to 2.5 min tidal breathing) \[[@CR35]\] in one \[[@CR29]\]. A normal result is a provocation concentration causing a fall in forced expired volume in 1 s (FEV~1~) of 20% (PC~20~) of \> 16 mg/mL for the former method \[[@CR34]\] and non-cumulative provocation dose causing a 20% FEV~1~ fall (PD~20~) of \> 400 μg for the latter \[[@CR35]\]. For analysis, PC~20~ values were converted to PD~20~s based on the validated relationship that a PC~20~ of 16 mg/mL equates to a post evaporation non-cumulative PD~20~ of 400 μg \[[@CR35]--[@CR38]\]. A normal (negative) mannitol result is a cumulative PD~15~ \> 635 mg \[[@CR3]\]. Mannitol responsiveness was also assessed as the dose--response slope (DRS) so that a value was available for all individuals. Fractional exhaled nitric oxide (FeNO) \[[@CR39]\] was available for all individuals. Data were analyzed with a computerized statistics programme, (Statistix 9 Analytical Software, Tallahassee, FL, USA). All data were log transformed. Log methacholine PD~20~ was compared to log mannitol DRS with linear regression and both log methacholine PD~20~ and log mannitol DRS were regressed with log FeNO.

Other studies {#Sec4}
-------------

Through a PubMed search, we identified 23 additional studies \[[@CR3]--[@CR25]\] that met the following criteria:Mannitol testing was performed by the standardized protocol and results reported as the PD~15~ \[[@CR3]\].Methacholine challenges by various methods were done in the same subjects, with one exception where more subjects had methacholine tests than mannitol tests \[[@CR25]\].The methacholine inhalation method was described.The definitions of "asthma" and "non-asthma" were outlined.

Results {#Sec5}
=======

Saskatoon studies {#Sec6}
-----------------

All 46 subjects had mild asthma and were not using inhaled corticosteroids (ICS). Age = 26.5 ± 8.5 (SD) years, height = 170 ± 9.6 cm, FEV~1~ = 3.45 ± 0.75 L and 91.5 ± 11.2% predicted. The methacholine PD~20~ was ≤ 400 μg in 45 of 46 (Fig. [1](#Fig1){ref-type="fig"}) and the geometric mean was 68.0 (95% CI 47.8--97.0) μg. The mannitol challenge was positive (PD~15~ ≤ 635 mg cumulative dose \[[@CR3]\]) in 22 of 46. The 635 mg PD~15~ cut off equates to a DRS of 42.3 (mg/%fall) (Fig. [1](#Fig1){ref-type="fig"}). There was a moderate positive correlation between log methacholine PD~20~ and log mannitol DRS (r = 0.51, p = 0.0003, Fig. [2](#Fig2){ref-type="fig"}). Both log methacholine PD~20~ and log mannitol DRS correlated significantly and negatively with log FeNO (r = 0.34 and r = 0.50, respectively, Fig. [3](#Fig3){ref-type="fig"}): The correlation with FeNO was stronger for mannitol (p = 0.0004) than for methacholine (p = 0.02).Fig. 1Individual data for methacholine PD~20~ in (μg) on the left and mannitol dose response slope (mg/% FEV~1~ fall) on the right. All values log transformed for analysis. The dotted red line, methacholine PD~20~ of 400 μg and mannitol DRS 42.3 (= mannitol PD~15~ of 635 mg), represents the cut points below which subjects are considered to have AHR to methacholine and mannitol respectively Fig. 2Mannitol DRS (mg/% FEV~1~ fall) on the vertical axis) and methacholine PD~20~ (μg) on the horizontal axis. The dotted red lines indicate the cut points below which the values indicate AHR to mannitol (42.3 mg/% FEV~1~ fall) or methacholine (400 μg) respectively. All values log transformed for analysis Fig. 3Correlation of FeNO on the vertical axis with methacholine PD~20~ (μg) on the horizontal axis left panel and mannitol DRS (mg/% FEV1 fall) on the horizontal axis right panel. All values log transformed

Methacholine dosimeter TLC studies {#Sec7}
----------------------------------

Of 27 studies where methacholine and mannitol were compared \[[@CR3]--[@CR29]\] 13 used dosimeter TLC methods for methacholine inhalation \[[@CR3]--[@CR15]\]. These 13 studies are summarized in Table [1](#Tab1){ref-type="table"}. The cut point for defining a positive methacholine test ranged from a cumulative PD~20~ of 7.8 to 10.2 μmol \[[@CR3]--[@CR6], [@CR8]--[@CR10], [@CR14]\], or a non-cumulative PC~20~ of 8 \[[@CR12]\] or 16 \[[@CR7], [@CR11], [@CR13], [@CR15]\] mg/mL (Table [2](#Tab2){ref-type="table"}). Assuming nebulizer characteristics similar to the methods outlined by the ATS in 2000 \[[@CR40]\], these would equate approximately to a non-cumulative post-evaporation PD~20~ between 200 and 400 μg. Four investigations studied known asthmatics \[[@CR3], [@CR6], [@CR8], [@CR15]\]; in one of these \[[@CR3]\] asthma was defined by indirect AHR to hypertonic saline. Four studies involved subjects with "doctor diagnosed asthma" \[[@CR5], [@CR9], [@CR12], [@CR13]\], while three other studies defined asthma from a cohort with non-diagnostic symptoms, by a respiratory physician \[[@CR7], [@CR10]\] or panel \[[@CR14]\] blinded to AHR data, and the final study defined asthma based on a positive AHR test (mannitol or methacholine) \[[@CR11]\]. The non-asthmatic cohorts included subjects remaining in 5 studies after asthmatics had been defined \[[@CR5], [@CR7], [@CR9], [@CR10], [@CR14]\], one study with normal controls \[[@CR13]\], one study with a highly select group of asymptomatic (non-asthmatic) individuals with positive methacholine tests \[[@CR4]\] and one study where non-asthma was define by negative AHR to both methacholine and mannitol \[[@CR11]\].Table 1Mannitol compared to methacholine deep inhalation studiesRefsnAsthma definitionnNon-asthma definitionAuthorRef1Anderson et al.\[[@CR3]\]25Asthma with indirect AHR to hypertonic saline02Pjorsgerg et al.\[[@CR4]\]016Asymptomatic positive MCT3Miedinger et al.\[[@CR5]\]14Asthma defined by board physician from101 Swiss firefighters87Defined by board MD4Pjorsberg et al.\[[@CR6]\]53Asthmatics not using ICS05Anderson et al.\[[@CR7]\]240240 of 375 with symptoms and unconfirmed asthmadiagnosis made by AHR-blinded physician135Defined by AHR-blinded physician6Gade et al.\[[@CR8]\]48Asthmatics same day tests in random order21 using ICS07Miedinger et al.\[[@CR9]\]42Doctor diagnosed (MD-Dx) asthma235 Swiss armed forces conscripts193Non-asthmatic conscripts8Sverrild et al.\[[@CR10]\]51From 238 randomly selected subjectsDx by physician blinded to AHR results187Blinded physician9Cancelliere et al.\[[@CR11]\]11From 28 with asthma-like SxDx defined by positive AHR17Defined by negative AHR10Manoharan et al.\[[@CR12]\]123MD-Dx asthma011Kim et al.\[[@CR13]\]50MD-Dx asthma54Normal controls12Backer et al.\[[@CR14]\]122From 190 referred for possible asthmaDx by panel without AHR results68Defined by panel without AHR results13Park et al.\[[@CR15]\]134Asthmatic children 32 using ICS0 Table 2Mannitol compared to methacholine deep inhalation methods and resultsMCH methodDefinition of positive MCHAsthmaAsthmaNon AsthmaNon AsthmaMCH +veMCH totalMAN +veMAN totalMCH +veMCH totalMAN +veMAN total1DeVilbiss 40PD20 ≤ 7.8 μmol^a^252525252Nebicheck DosimeterPD20 ≤ 8.0 μmol^a^16161163Mefar dosimeterPD20 ≤ 2 mg^a^--10.2 μmol91112137863864Nebicheck DosimeterPD20 ≤ 8.0 μmol^a^435343535ATS DosimeterPC20 ≤ 16 mg/mL12224013224034135361356Mefar dosimeter^b^PD20 ≤ 2 mg^a^--10.2 μmol224822487Spira dosimeterPD20 ≤ 8.0 μmol^a^1842174215193141938Spira dosimeterPD20 ≤ 8.0 μmol^a^355130513718731879Spira dosimeterPC20 ≤ 16 mg/mL911101101701710Mefar dosimeterPC20 ≤ 8 mg/mL741237612311Chai dosimeterPC20 ≤ 16 mg/mL2250245015445412Jaeger dosimeterPD20 ≤ 7.8 μmol^a^79122461223268116813Spira dosimeterPC20 ≤ 16 mg/mL90134100134Total%54860.2%91053758.9%91214218.8%756729.5%756Exclude studies 1, 2 and 9Total%51458.8%87450257.3%87612617.4%723719.8%723^a^PD~20~ Calculated cumulatively^b^PD~20~ and PD~15~ calculated manually form response-dose ratio slope graphs

Results from the 12 asthma studies (Table [2](#Tab2){ref-type="table"}) show similar sensitivity with positive methacholine tests in 60.2% (548 of 910) asthmatics and positive mannitol tests in 58.9% (537 of 912) asthmatics. When the two studies in which asthma was defined based on presence of AHR \[[@CR3], [@CR11]\] were excluded, the results were similar with 58.8% and 57.3% positive for methacholine and mannitol respectively (Table [2](#Tab2){ref-type="table"}). In the 8 studies with non-asthma cohorts \[[@CR4], [@CR5], [@CR7], [@CR9]--[@CR11], [@CR13], [@CR14]\], there were approximately twice as many positive methacholine tests (18.8% or 142 of 756) compared to mannitol tests (9.5% or 72 of 756) Table [2](#Tab2){ref-type="table"}) Excluding the two studies in which AHR was either an inclusion \[[@CR4]\] or an exclusion \[[@CR11]\] criterion produced similar results, 17.4% and 9.8% positive for methacholine and mannitol respectively (Table [2](#Tab2){ref-type="table"}).

Methacholine tidal breathing studies {#Sec8}
------------------------------------

The 13 studies using tidal breathing methacholine methods \[[@CR16], [@CR18]--[@CR29]\] compared to mannitol are summarized in Table [3](#Tab3){ref-type="table"}. A fourteenth study that used histamine as the direct stimulus was also included \[[@CR17]\]. Methacholine was inhaled by 2 min of tidal breathing from a jet nebulizer in 9 studies \[[@CR16], [@CR19], [@CR21], [@CR22], [@CR24]--[@CR28]\] or from a vibrating mesh nebulizer in one study \[[@CR29]\]. The remaining four studies were defined as tidal breath dosimeter methods \[[@CR17], [@CR18], [@CR20], [@CR23]\]. The cut point definitions for a positive methacholine test (Table [4](#Tab4){ref-type="table"}) included a cumulative PD~20~ of 1 to 2 mg (5.1--10.2 μmol) \[[@CR17], [@CR18], [@CR20]\] or 8 μmol \[[@CR23]\], a non-cumulative PC~20~ of 8 \[[@CR23]\] or 16 \[[@CR16], [@CR19], [@CR21], [@CR24]--[@CR28]\] mg/mL and a non-cumulative post-evaporation PD~20~ of 400 μg \[[@CR29]\]. Once again, assuming nebulizer characteristics similar to the methods outlined by the ATS in 2000 \[[@CR40]\] these would equate approximately to a non-cumulative post-evaporation PD~20~ between 200 and 400 μg. Known asthmatics were evaluated in 11 studies \[[@CR16], [@CR17], [@CR20]--[@CR22], [@CR25]--[@CR29]\] doctor diagnosed asthma in athletes in two studies \[[@CR18], [@CR23]\] and, from a group of symptomatic subjects, asthma diagnosed by a respiratory physician prior to AHR determination in one study \[[@CR24]\] (Table [4](#Tab4){ref-type="table"}). The 7 studies involving non-asthmatic cohorts included non-asthmatic controls in four \[[@CR16], [@CR17], [@CR20], [@CR25]\], the athletes remaining after doctor diagnosed asthma had been defined in two \[[@CR18], [@CR23]\], and the symptomatic individuals remaining after asthma was diagnosed \[[@CR24]\] (Table [4](#Tab4){ref-type="table"}).Table 3Mannitol compared to methacholine tidal breathing studiesReferencenAsthma definitionnNon asthma definitionAuthorRef \#1Subbarao et al.\[[@CR16]\]25Asthmatic children with positive methacholine test10Non asthmatic methacholine negative2Koskelka et al.\[[@CR17]\]37Mild corticosteroid naïve asthmaticsNB: Histamine10Non asthmatic controls3Sue-Chu et al.\[[@CR18]\]10MD-Dx asthma from 58 cross country skiers48Non asthmatic cross country skiers4Andregnette et al.\[[@CR20]\]30Current asthmatic children05Aronsson et al.\[[@CR19]\]34Asthmatics18Non asthmatic controls6Lemiere et al.\[[@CR21]\]30Occupational asthmatics07Andregnette et al.\[[@CR22]\]23Asthmatic children with EIB symptoms08Toennesen et al.\[[@CR23]\]18MD-Dx asthma from 57 elite athletes39Non asthmatic Elite athletes9Porpodis et al.\[[@CR24]\]67From 88 subjects with asthma-like symptoms21Symptoms but no asthma10Gutierrez et al.\[[@CR25]\]156Asthmatic children38Non asthmatic controls11Cockcroft et al.\[[@CR26]--[@CR28]\]26Mild asthma no ICS012Blais et al.\[[@CR29]\]20Mild asthma no ICS0 Table 4Mannitol compared to methacholine tidal breathing methods and resultsMCH MethodDefinition of positive MCHAsthmaAsthmaNon asthmaNon asthmaMCH +veMCH totalMAN +veMAN totalMCH +veMCH totalMAN +veMAN total12 min TB (ref Cockcroft et al \[[@CR34]\])PC20 ≤ 16 mg/mL252521250100102Spira tidal dosimeterPD20 ≤ 1 mg^a^ (Hist.)303719373Spira tidal dosimeterPD20 ≤ 1814 μg^a^41021019481484TB (ref Cockcroft et al \[[@CR34]\])PC20 ≤ 16 mg/mL293013305Jaeger tidal dosimeterPD20 ≤ 2 mg^a^2734133431801862 min TB (ref Cockcroft et al \[[@CR34]\])PC20 ≤ 16 mg/mL22309307TB (ref Cockcroft et al \[[@CR34]\])PC20 ≤ 8 mg/mL182310238Spira tidal dosimeterPD20 ≤ 8 μmol^a^15169181393399TB (ref Cockcroft et al \[[@CR34]\])PC20 ≤ 16 mg/mL42674367321021102 min TB (ref Cockcroft et al \[[@CR34]\])PC20 ≤ 16 mg/mL131141777130021112 min TB (3 studies) \[[@CR34]\]PC20 ≤ 16 mg/mL2526112612Solo TB (1.5--2.5 min) \[[@CR35]\]PD20 ≤ 400 μg20201120Total%34383.1%41314641.5%3512716.2%16642.5%157^a^PD~20~ calculated cumulatively

Results are summarized in Table [4](#Tab4){ref-type="table"}. Methacholine tests were more than twice as likely to be positive in asthmatics (i.e. methacholine more sensitive) than was mannitol. The positive rate was 83.1% (343 of 413) for methacholine and 41.5% (146 of 351) for mannitol. In the non-asthmatics methacholine was more likely to be positive at 16.2% (27 of 166) than was mannitol at 2.5% (4 of 157).

When both methacholine TLC and methacholine TB studies were combined, the overall rate of a positive mannitol challenge in non-asthmatics was 8.3% or 76 of 913.

Discussion {#Sec9}
==========

These data provide strong support for the hypothesis that tidal breathing direct methacholine challenge methods yield results that are substantially more sensitive for asthma than does the indirect mannitol challenge. By contrast, when methacholine is inhaled by TLC methods, the diagnostic sensitivity falls to a level similar to that seen with mannitol.

Many investigators have found that AHR correlates with airway inflammation, primarily with eosinophils, as assessed by broncho-alveolar lavage (BAL), induced sputum cell counts or indirectly by FeNO or blood eosinophils \[[@CR41]--[@CR47]\]. Initial studies addressed methacholine (direct) AHR and BAL eosinophils and metachromatic cells (basophils and mast cells) \[[@CR41], [@CR42]\]. Subsequent studies addressed, in addition, indirect challenges, AMP \[[@CR43], [@CR44]\], bradykinin \[[@CR45]\] and mannitol \[[@CR26], [@CR29], [@CR46], [@CR47]\]. While these investigations show a fair to good correlation between methacholine AHR and primarily eosinophilic inflammation, the indirect AHR tests correlate substantially better with inflammation \[[@CR43]--[@CR46]\]. The results from our combined investigations \[[@CR26]--[@CR29]\], using FeNO as an indirect measure of eosinophilic airway inflammation, are in keeping with this as shown in Fig. [3](#Fig3){ref-type="fig"}. Relatively few studies have addressed the potentially more important \[[@CR48]\] metachromatic cells (mast cells and/or basophils) \[[@CR41], [@CR42], [@CR47]\]. There is a hint from these studies that airway metachromatic cell inflammation may correlate better with AHR than does eosinophilic airway inflammation.

AHR improves with anti-inflammatory therapeutic strategies including allergen avoidance environmental control \[[@CR49], [@CR50]\] and ICS \[[@CR51]--[@CR53]\]. In keeping with the above observations, indirect AHR (AMP \[[@CR49]--[@CR52]\]) shows greater improvement with these treatments than does direct methacholine AHR. Mannitol responsiveness improves greatly after ICS treatment \[[@CR53]\] and can provide a useful predictive marker of a pending asthma exacerbation during ICS tapering \[[@CR54]\]. Although direct AHR has been proposed to monitor and guide asthma treatment \[[@CR55]\], indirect AHR may provide a particularly valuable tool as a guide to monitoring asthma control \[[@CR56]\]. In fact, non-responsiveness to indirect challenge (e.g. AMP, mannitol) may be a goal for adequate asthma control with ICS \[[@CR56]\]. This, of course, is consistent with a positive indirect AHR challenge (including mannitol) being insensitive for the diagnosis of well controlled asthma.

Deep inhalations to TLC produce potent bronchodilation and bronchoprotection, the latter greater than the former, in normal individuals but initially stated to not occur in asthmatics \[[@CR57]\]. It had become apparent that this marked bronchoprotective effect extends to mild asthmatics \[[@CR30]--[@CR33]\] and, in all likelihood may well extend to well controlled asthmatics. Although not seen in all studies \[[@CR58]\], eosinophilic airway inflammation impairs the bronchoprotective effect of deep inhalation \[[@CR26], [@CR59], [@CR60]\]. Anti-inflammatory strategies, both allergen avoidance \[[@CR61]\] and oral/inhaled corticosteroid \[[@CR62]\], can restore or improve the deep inhalation bronchoprotection in asthmatics. In one study, lack of bronchoprotection (methacholine) and elevated levels FeNO as an indirect measure of airway inflammation were associated with indirect AHR to mannitol \[[@CR26]\].

Collectively, these data suggest that airway inflammation (eosinophilic particularly), indirect AHR and loss of deep inhalation bronchoprotection will occur together in asthmatics. Conversely, deep inhalation bronchoprotection and low levels of airway inflammation will be associated with little if any indirect AHR \[[@CR26]\]. Avoidance of TLC inhalations during methacholine inhalation will therefore result in many more positive direct challenge tests in mild (and possibly well controlled) asthmatics with no indirect AHR and minimal airway inflammation. This is confirmed by our current review.

Deep inhalation bronchoprotection during methacholine challenges is an important and underappreciated phenomenon \[[@CR33]\]. This has been shown by three studies from our laboratory \[[@CR30]--[@CR32]\] and supported by studies from other laboratories \[[@CR63], [@CR64]\]. This was first suggested in a study of 40 individuals \[[@CR30]\] comparing the two methacholine methods outlined in the ATS document \[[@CR40]\]. Follow up investigations demonstrated that asthmatics with negative TLC dosimeter methacholine tests had positive challenges when the identical dosimeter dose was administered with sub-maximal inhalations (approximately half TLC) \[[@CR31]\] and that many asthmatics with positive tidal breathing methacholine challenges were negative when five TLC breaths were incorporated at equal intervals throughout the 2 min of tidal breathing \[[@CR32]\]. These latter two studies provide convincing evidence of the bronchoprotective effect of deep TLC inhalations in many individuals with mild asthma. Our summary data from 55 asthmatic individuals with positive tidal breathing methacholine tests revealed that 13 (24%) had negative five TLC breath dosimeter methacholine tests \[[@CR33]\]. This represents 50% of asthmatics with a tidal breathing PC~20~ between 2 and 16 mg/mL (post evaporation non-cumulative PD~20~ between 50 and 400 μg). This is exactly the range where a positive diagnostic methacholine challenge, done in individuals with symptoms suggestive of asthma and normal spirometry, is likely to fall. In this population, the TLC dosimeter methacholine method could, therefore, produce a false negative rate approaching 50% for individuals with asthma and mild AHR. For these reasons the recent methacholine guidelines have strongly suggested that methacholine challenges be performed with tidal breathing methods with a non-TLC dosimeter method as a second option \[[@CR36]\]. By contrast, as anticipated by the above data, our recent study documented that removal of TLC inhalations from the mannitol challenge did not affect the result \[[@CR29]\].

It is difficult to accurately comment on sensitivity and specificity of the different tests from the available references. A reasonable estimate of diagnostic sensitivity can be made by assessing the rate of positivity in subjects determined to have asthma. Based on this approach the tidal breathing methacholine test is about twice as sensitive for "asthma" as the mannitol test (83.1% and 41.5% respectively) in the studies assessed, whereas the sensitivities of TLC methacholine and mannitol tests were similar, at approximately 60% for both in the studies included. These data suggest that the loss of diagnostic sensitivity of the methacholine test when using a TLC dosimeter method is significant enough to make the sensitivity equivalent to an indirect challenge. It is even more difficult to comment accurately on specificity without a larger cohort of normal non-asthmatic individuals. The observation that there were fewer positive mannitol tests (about half) compared to methacholine tests in non-asthmatics is consistent with the consensus that indirect challenges, including mannitol, are more specific for asthma \[[@CR2], [@CR65]\]. The difficulties are further compounded both by the lack of an independent gold standard for the diagnosis of asthma and by the requirement for the symptoms under investigation to be clinically current, i.e. within the past few days \[[@CR65], [@CR66]\].

We suspect that these results would translate to indirect challenges other than mannitol; these include AMP, propranolol, hypertonic saline, EVH and exercise (EIB). It is likely that all these indirect challenges would show minimal if any deep inhalation bronchoprotection. EVH and EIB are particularly important. It would, however, be difficult to design a study with and especially without deep inhalations for these two, especially for EVH.

Indirect challenges require a substantially larger dose of stimulus than direct challenges, up to or greater than three orders of magnitude mg for mg or mmol for mmol \[[@CR65]\]. For example, the top doses for mannitol and methacholine are 635 (cumulative) and 0.4 mg (non-cumulative) respectively. It is possible that mannitol might be more sensitive than many other indirect stimuli because the challenge is less likely to be "dose limited" \[[@CR65]\]. There are physiologic limits on the "dose" of stimulus that can be achieved with exercise or EVH, and, because of the large doses needed, a solubility limit on the doses that can be achieved with AMP or propranolol \[[@CR65]\]. Mannitol, by contrast, is a dry powder inhalation and the dose is not limited by solubility. There is only one mannitol inhalation method \[[@CR3]\]. However, the large number of different methacholine methods represents a difficulty when attempting to compare data. A conservative estimate is that there were at least 6 different TLC dosimeter methods and 4 different TB methods in the studies evaluated. The best case estimate is that these methods equated to a post-evaporation methacholine PD~20~ range of only twofold (200--400 μg), however that is speculation without knowledge of the operating characteristics of the different nebulizers used.

Conclusion {#Sec10}
==========

The discordance between methacholine and mannitol comparisons can be explained by the method of methacholine inhalation. Tidal breathing methacholine tests are substantially more sensitive than mannitol tests for a diagnosis of asthma and equally more sensitive than TLC dosimeter methacholine methods. In order to preserve a high diagnostic sensitivity, methacholine challenges should be performed by tidal breathing \[[@CR33], [@CR36], [@CR65]\], thus providing data that are complementary to the more specific mannitol challenge.
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